Table 1 Clinical characteristics of HER2-positive breast cancer patients and the univariate analysis of predictive biomarkers of the response to anthracyclines

Age

45 years

34 (30%)

10

24

0.975

3

31

0.450

≥45 years

79 (70%)

23

56

11

68

Menopausal status

Postmenopausal

69 (61%)

20

49

0.949

7

62

0.364

Premenopausal

44 (39%)

13

31

7

37

Regimen

 CEF

55 (49%)

15

40

0.660

9

46

0.212

 NE

58 (51%)

18

40

5

53

Tumor size

≤5 cm

46 (41%)

21

25

0.001

4

42

0.323

>5 cm

67 (59%)

12

55

10

57

Lymph node status

0

43 (38%)

-

-

-

-

-

-

1 to 3

31 (27%)

-

-

-

-

-

-

4 to 9

25 (22%)

-

-

-

-

-

-

≥10

14 (13%)

-

-

-

-

-

-

Pre-estrogen receptor

Negative

78 (69%)

21

57

0.426

10

68

0.835

Positive

35 (31%)

12

23

4

31

Pre-progesterone receptor

Negative

83 (73%)

24

59

0.911

9

74

0.518

Positive

30 (27%)

9

21

5

25

Pre-pMAPK

Negative

34 (30%)

13

21

0.166

8

26

0.855

Positive

79 (70%)

20

59

6

73

Pre-pAKT

Negative

30 (27%)

14

16

0.014

4

26

0.855

Positive

83 (73%)

19

64

10

73

Pre-PTEN

Negative

40 (35%)

13

27

0.568

5

35

0.979

Positive

73 (65%)

20

53

9

64

Pre-P27

Negative

35 (31%)

15

20

0.432

5

40

0.737

Positive

68 (69%)

18

50

9

59

Pre-IGF-1R

Negative

47 (42%)

12

35

0.469

5

42

0.634

Positive

66 (58%)

21

45

9

57

Pre-cyclinD1

Negative

42 (37%)

14

28

0.458

4

38

0.477

Positive

71 (63%)

19

52

10

61

Pre-Ki67

Negative

43 (38%)

15

28

0.298

2

41

0.076

Positive

70 (62%)

18

52

12

58